Journal of Pharmaceutical Practice and Service 2025;43(12):614-618
doi:10.12206/j.issn.2097-2024.202402034
Reasonable management and control practice of prophylactic use of antibiotics in urinary system lithotripsy
Yijun CHEN 1 ; Zhuo WANG 2 ; Miao HE 2 ; Yu ZHANG 2 ; Jing TIAN 2
Affiliations
Keywords
urinary system lithotripsy; antibiotics; prophylactic use; reasonable management and control; indexes related to antibiotics
Country
China
Language
Chinese
Abstract
Objective To analyze the effectiveness of reasonable control measures for prophylactic use of antibiotics in urinary system lithotripsy. Methods By antimicrobial stewardship, strengthening special comments on antibiotics and information notification on rational use of antibiotics, adding and improving the pre-review rules for antibiotics prescriptions, conducting in-depth clinical training and consultation by clinical pharmacists, strengthening innovation in rational use of drugs, and taking various measures to actively improve rational use of prophylactic antibiotics of lithotripsy in urology department, the changes of indexes related to antibiotics in urology department from 2019 to 2022 were analyzed. Results After active and reasonable control, Antibiotics Use Density in urology department decreased year by year. The utilization rate of antibiotics in inpatients decreased from 94.27% in 2019 to 77.47% in 2022. Various rate of microbial inspection reached the standard in 2022. The imipenem and cilastatin sodium for injection ranking of prophylactic use of antibiotics consumption DDDs for urinary system lithotripsy decreased from the 4th place in 2019 to the 8th place in 2022. The ranking of the urology department on carbapenem consumption DDDs in the whole hospital decreased from the 8th place in 2019 to the 12th place in 2022. At the same time, the incidence of urinary tract lithotripsy postoperative infection showed a decreasing trend year by year, from 0.84% in 2019 to 0.49% in 2022. Conclusion Positive control measures can promote the rational use of prophylactic antibiotics for urinary system lithotripsy.
备案号: 11010502037788, 京ICP备10218182号-8)